Home Services Immuno-Oncology T Cell Killing Assay

T Cell Killing Assay

Tumour Killing Assays

Understanding whether a test biologic or small molecule can enhance tumour cell killing could well be a key component of your drug discovery program.

To assist, Aquila offers cell-mediated cytotoxicity (CMC) and antibody-dependent cytotoxic (ADCC) assays, using traditional label-release, to help you assess immune cell driven apoptosis of cultured tumour cells.

Our ADCC assays can be adapted to a range of tumour types and immune cell populations, such as T cells, NK cells, macrophages and neutrophils. They can also incorporate anti-TAA antibodies.

Please get in touch to learn more about our T Cell Killing Assays.

How our assays work

Tumour cells are labelled and seeded into a 96-well plate, and incubated with the immune cell population of interest. We label the cells with a caspase 3/7-sensitive dye to allow real-time visualisation of tumour cell proliferation and apoptosis using the IncuCyte ZOOM® imaging system.

We offer custom and standard readout options, including assessing cytokine levels (e.g. IFN-╬│) by ELISA or multiplex, and flow cytometric analysis of recovered immune cells.